| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3907 | Ono-ae2-227 | EP(4)-selective antagonist |
|
| DCC3908 | Ono-ae-248 | Novel selective EP3 receptor agonist |
|
| DCC3909 | Ono-ae3-237 | Potent, selective, and orally active prostaglandin D2 receptor antagonist |
|
| DCC3910 | Oopz-23-l(nle)aq | Novel potent inhibitor of protein-protein interactions |
|
| DCC3911 | Opc-13213 | Metabolite of Cilostazol |
|
| DCC3912 | Opc-14117 | Antioxidant and free radical scavenger, attenuating edema formation, and subsequent tissue damage following cortical contusion |
|
| DCC3913 | Ophiobolin A | Inhibitor of calmodulin action in calcium regulation |
|
| DCC3914 | Optoglunam4.1 | Novel negative allosteric modulator (NAM) of mGlu4, being isomerized with blue-light/dark cycles with fast relaxation |
|
| DCC3915 | Orc-13661 Hydrochloride | Novel Potent, Well Tolerated, and Orally Active Protective Agent against Aminoglycoside-Induced Hearing Loss |
|
| DCC3916 | Orcein | Collagen immunostain |
|
| DCC3917 | Orex-1019 | Novel mixed κ/μ receptor antagonist. having therapeutic potential for the treatment of depression and other stress-induced conditions |
|
| DCC3918 | Org-27759 | Negative allosteric modulator at the CB1 receptor |
|
| DCC3919 | Org-29647 | CB1 allosteric modulator |
|
| DCC3920 | Org48762-0 | Selective p38alpha and p38beta kinase inhibitor |
|
| DCC3921 | Oritavancin | Lipoglycopeptide Antibacterial, acting as a inhibitor of Cytochrome P450 2C19/2C9, and a inducer of Cytochrome P450 3A4/2D6 |
|
| DCC3922 | orm-10103 | Novel sodium/calcium exchanger (NCX) inhibitor |
|
| DCC3923 | Orn0829 | Novel potent dual orexin 1/2 receptor (OX1/2R) antagonist for the treatment of insomnia |
|
| DCC3924 | Oroidin Hydrochloride | Inhibitor of an enzyme responsible for the multidrug resistance phenotype in the yeast Saccharomyces cerevisiae. |
|
| DCC3925 | Orp-101 | Peripheral weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist, preventing from being absorbed and entering the central nervous system |
|
| DCC3926 | Ortataxel | Second-generation taxane derivative with potential antineoplastic activity, binding to and stabilizing tubulin molecules, inhibiting cell division and cellular proliferation |
|
| DCC3927 | Oseltamivir Hydrochloride | Inhibitor of the influenza neuramidase enzyme, blocking neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles |
|
| DCC3928 | Osi-296 | Novel potent, orally efficacious, dual inhibitor of cMET and RON kinases |
|
| DCC3929 | Osi-461 | Novel cGMP phosphodiesterase (cGMP-PDE) inhibitor |
|
| DCC3930 | Osl-95ii | Inhibitor of the glycan-processing enzyme endoplasmic-reticular glucosidase |
|
| DCC3931 | Osteoclast Differentiation Inhibitor T63 | Novel inhibitor of osteoclast differentiation through regulating MAPKs and Akt signaling pathways |
|
| DCC3932 | Osteoprotegerin | Soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage |
|
| DCC3933 | Osteosarcoma-in-d14 | Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes |
|
| DCC3934 | Osteosarcoma-in-d15 | Novel Inhibitor of Migration and Invasion of Osteosarcoma Cells Mediated by p53, Regulating EMT-Related Genes |
|
| DCC3935 | Osu-53 | Novel AMPK activator, inhibiting mTOR signaling and autophagy stimulation, activating mutations in RAS or BRAF |
|
| DCC3936 | Ota-5781 | Novel potent inhibitor of the natural function of FDX1, promoting a unique form of copper-dependent cell death |
|
